Document is current

Article History

Received: 18 June 2020

Accepted: 15 March 2021

First Online: 8 April 2021

Competing interests

: S.D.C.: fees for medical education from Novartis and Pierre-Fabre; recipient of the IG20774 of Fondazione Associazione Italiana Ricerca contro il Cancro (AIRC). J.M.P.-G.: consultant/advisory board member for Roche, Lilly; travel, accommodation paid by Roche. A.L.-C.: leadership role for Eisai, Celgene, Lilly, Pfizer, Roche, Novartis, Roche, MSD; stock or other ownership in MEDSIR and Initia-Research; consultant/advisory board member for Lilly, Roche, Pfizer, Novartis, Pierre-Fabre, Genomic Health, GSK; speakers’ bureau honoraria from Lilly, Astra Zeneca, MSD; research funding to the Institution from Roche, Foundation Medicine, Pierre-Fabre, Agendia; travel, accommodation paid by Roche, Lilly, Novartis, Pfizer, AstraZeneca. J.C.: stock or other ownership in MEDSIR; consultant/advisory board member for Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Servier, Merck Sharp&Dohme, GSK, Leuko, Bioasis, Clovis Oncology; honoraria from Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp&Dohme, Daiichi Sankyo; research funding to the Institution from Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F. Hoffman-La Roche, Guardant Health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Puma C, Queen Mary University of London. A.M., A.G., L.M., and C.H. are full-time employers of MEDSIR.